Company registration number 1528826 (England and Wales)
K.P. BIOPLEX LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
K.P. BIOPLEX LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
K.P. BIOPLEX LIMITED
BALANCE SHEET
AS AT 30 NOVEMBER 2025
30 November 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
48,000
48,000
Current assets
-
-
Creditors: amounts falling due within one year
4
(15,786)
(15,786)
Net current liabilities
(15,786)
(15,786)
Net assets
32,214
32,214
Capital and reserves
Called up share capital
100
100
Revaluation reserve
5
32,769
32,769
Profit and loss reserves
(655)
(655)
Total equity
32,214
32,214

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 24 July 2026 and are signed on its behalf by:
Ms M C Miers
Director
Company registration number 1528826 (England and Wales)
K.P. BIOPLEX LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 2 -
1
Accounting policies
Company information

K.P. Bioplex Limited is a private company limited by shares incorporated in England and Wales. The registered office is Court House, Court Road, Bridgend, Wales, CF31 1BE.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, The principal accounting policies adopted are set out below.

1.2
Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold land and buildings
Not Depreciated
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
K.P. BIOPLEX LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 3 -
3
Tangible fixed assets
Land and buildings
£
Cost
At 1 December 2024 and 30 November 2025
48,000
Depreciation and impairment
At 1 December 2024 and 30 November 2025
-
0
Carrying amount
At 30 November 2025
48,000
At 30 November 2024
48,000
4
Creditors: amounts falling due within one year
2025
2024
£
£
Other creditors
15,786
15,786
5
Revaluation reserve
2025
2024
£
£
At the beginning and end of the year
32,769
32,769
2025-11-30 2024-12-01 false false true 24 July 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Ms Maria Coral Miers Ms Shereen Parrish Ms S Parrish 1528826 2024-12-01 2025-11-30 1528826 2025-11-30 1528826 2024-11-30 1528826 core:LandBuildings 2025-11-30 1528826 core:LandBuildings 2024-11-30 1528826 core:WithinOneYear 2025-11-30 1528826 core:WithinOneYear 2024-11-30 1528826 core:ShareCapital 2025-11-30 1528826 core:ShareCapital 2024-11-30 1528826 core:RevaluationReserve 2025-11-30 1528826 core:RevaluationReserve 2024-11-30 1528826 core:RetainedEarningsAccumulatedLosses 2025-11-30 1528826 core:RetainedEarningsAccumulatedLosses 2024-11-30 1528826 bus:Director1 2024-12-01 2025-11-30 1528826 core:LandBuildings core:OwnedOrFreeholdAssets 2024-12-01 2025-11-30 1528826 2023-12-01 2024-11-30 1528826 core:LandBuildings 2024-11-30 1528826 core:CurrentFinancialInstruments 2025-11-30 1528826 core:CurrentFinancialInstruments 2024-11-30 1528826 bus:EntityNoLongerTradingButTradedInPast 2024-12-01 2025-11-30 1528826 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 1528826 bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 1528826 bus:FRS102 2024-12-01 2025-11-30 1528826 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 1528826 bus:Director2 2024-12-01 2025-11-30 1528826 bus:CompanySecretary1 2024-12-01 2025-11-30 1528826 bus:FullAccounts 2024-12-01 2025-11-30 xbrli:pure xbrli:shares iso4217:GBP